SAVE THE DATE:
Leuven,
The meeting, intended for investors and analysts, will provide an overview of the Company’s development pipeline and corporate strategy, which is focused on successfully creating an industry leading DME franchise.
Presentations will be delivered by members of Oxurion’s senior management team and by two global Key Opinion Leaders in the field of retinal vascular disorders:
Ramin Tadayoni , M.D., Ph.D. is Professor of ophthalmology atUniversity of Paris . He is head of the Ophthalmology Departments at Lariboisière,St Louis and Rothschild Foundation Hospitals inParis, France .
Arshad Khanani , M.D., M.A., is Managing Partner, Director of Clinical Research, Director of Fellowship atSierra Eye Associates , and Clinical Associate Professor at theUniversity of Nevada, Reno , US.
The agenda and details of how to join the meeting will be available in an invitation and on the Company’s website (www.Oxurion.com) which will be issued closer to the time of the event.
END
For further information please contact:
Global Head of Investor Relations & Corporate Communications Tel: +32 16 75 13 10 / +32 478 33 56 32 wouter.piepers@oxurion.com | Tel: +44 20 7638 9571 oxurion@citigatedewerogerson.com |
About
- THR-149, a plasma kallikrein inhibitor being developed as a potential new standard of care for DME patients who respond sub-optimally to anti-VEGF therapy.
THR-149 has shown positive topline Phase 1 results for the treatment of DME. The Company is currently conducting a Phase 2 clinical trial evaluating THR-149 with DME-patients who previously responded sub-optimally to anti-VEGF therapy.
THR-149 was developed in conjunction withBicycle Therapeutics PLC (NASDAQ: BCYC)
- THR-687, is a pan-RGD integrin inhibitor, that is initially being developed as a potential new standard of care for all DME patients. Positive topline results in a Phase 1 clinical study assessing it as a treatment for DME were announced in
January 2020 . THR-687 is expected to enter a Phase 2 clinical trial by mid-2021.
THR-687 is an optimized compound derived from a broader library of integrin inhibitors in-licensed from Galapagos NV (Euronext & NASDAQ: GLPG).
More information is available at www.oxurion.com.
Important information about forward-looking statements
Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of
© OMX, source